Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Pharmakologie_EN.png
 
AKH_en.png
 
 
Hauptnavigation
  • Home
  • General Information
  • Organization
  • Education / Clinical Training
  • Science & Research
 
Organization / Section of Hematology & Immunology
 
Subnavigation
  • Section of Cardiovascular Medicine
  • Section of Clinical Pharmacokinetics / Pharmacogenetics and Imaging
  • Section of Hematology & Immunology
    • Team
  • Section of Ophthalmo-Pharmacology
  • Working Group Drug-Development and Healthcare
  • Study Nurses


Inhaltsbereich

Section of Hematology & Immunology

Bernd Jilma

Bernd Jilma, M.D.

Professor and Section Head

» Curriculum Vitae

Researcher Profile

 

Mission Statement

Our focus is to test newly developed drugs in the immunologic and coagulation field.

We try to combine in vitro, ex vivo and in vivo trials to obtain an integrated insight into pathophysiologic processes.

 

Current Projects

  1. First in man trials including basket trials with chemokines, cytokines, antibodies, aptamers and biosimilarity trials with biologicals
     
  2. Drug trials in human LPS infusion or lung instillation model to measure pharmacodynamics of novel compounds under standardized conditions of inflammation.
     
  3. Phase I-III patient trials, to monitor immunmodulation and coagulation in various diseases including stroke.
     
  4. Target on vessels, platelets and coagulation: Platelet hyperfunction in myocardial infarction, thrombotic microangiopathies, critically ill, extracorporeal circulations (hemodialysis, cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist devices)
     
  5. Development of recombinant human diamine oxidase against mast cell activation disorders and anaphylaxis

 

 

 

Key Publications

1. Gludovacz E, Schuetzenberger K, Resch M, Tillmann K, Petroczi K, Schosserer M, Vondra S, Vakal S, Klanert G, Pollheimer J, Salminen TA, Jilma B, Borth N, Boehm T: Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmceutical. Elife. 2021 Sep 3;10:e68542. doi:  10.7554/eLife.68542

2. Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S: Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8; 384(14):1323-1334. doi:10.1056/NEJMoa2027760.

3. Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, Valent P, Jilma B: Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylasis in mastocytosis patients. Allergy 2019 Mar;74(3):583-593. doi: 10.1111/all.13663

4. Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B: Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin. Blood 2019 Feb 28;133(9):893-901. doi: 10.1182/blood-2018-06-856930

5. Peyvandi F, Sully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni W, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichs H, Duby C, Tersago D: TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombozytopenic Purpura. New Entl J Med. 2016 Feb11;374(6):511-522. doi: 10.1056/NEJMoa1505533






For information please contact our Section Head:
Bernd Jilma, MD
E-Mail: bernd.jilma@meduniwien.ac.at

 
Print
 

Quick Links

 
-- Links
-- Department Folder
-- ISO Certificate
-- Announcement §43a AMG
    (in German)

-- Coordination Centre for
    Clinical Studies (KKS)

-- Contact
 
 

Featured

 
 
 
 
 
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact